B. Riley Estimates Lineage Cell Therapeutics FY2028 Earnings

Key Points

• B. Riley has revised its earnings per share (EPS) estimate for Lineage Cell Therapeutics for FY2028 from $0.20 to $0.15, while the consensus estimate remains at ($0.12) per share.
• Analysts have a consensus "Buy" rating for Lineage Cell Therapeutics, with price targets ranging from $2.00 to $9.00 per share.
• Lineage Cell Therapeutics' stock is currently trading at $1.20, with a 52-week range between $0.37 and $1.31.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Research analysts at B. Riley cut their FY2028 EPS estimates for shares of Lineage Cell Therapeutics in a note issued to investors on Friday, August 15th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings of $0.15 per share for the year, down from their prior forecast of $0.20. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share. B. Riley also issued estimates for Lineage Cell Therapeutics' FY2029 earnings at $0.11 EPS.

LCTX has been the subject of a number of other research reports. D. Boral Capital reissued a "buy" rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Thursday, August 14th. HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, June 23rd. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $4.25.

Lineage Cell Therapeutics Trading Up 4.7%

NYSEAMERICAN LCTX traded up $0.0550 during trading on Monday, reaching $1.2250. The company's stock had a trading volume of 559,572 shares, compared to its average volume of 1,909,070. The firm has a market capitalization of $279.74 million, a price-to-earnings ratio of -6.81 and a beta of 1.66. Lineage Cell Therapeutics has a 12 month low of $0.3651 and a 12 month high of $1.31. The firm has a 50 day moving average price of $1.02 and a 200 day moving average price of $0.70.

Institutional Trading of Lineage Cell Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP purchased a new stake in Lineage Cell Therapeutics during the second quarter worth about $44,000. Brevan Howard Capital Management LP purchased a new stake in Lineage Cell Therapeutics during the second quarter worth about $281,000. Raymond James Financial Inc. increased its holdings in Lineage Cell Therapeutics by 136.2% during the second quarter. Raymond James Financial Inc. now owns 69,380 shares of the company's stock worth $63,000 after buying an additional 40,009 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Lineage Cell Therapeutics in the second quarter worth about $35,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Lineage Cell Therapeutics in the second quarter worth about $69,000. Hedge funds and other institutional investors own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.